Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Gains from Investment Securities (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Gains from Investment Securities for 6 consecutive years, with $9.4 million as the latest value for Q4 2024.

  • On a quarterly basis, Gains from Investment Securities rose 118.99% to $9.4 million in Q4 2024 year-over-year; TTM through Dec 2024 was $9.4 million, a 1139.36% increase, with the full-year FY2024 number at $9.4 million, up 16.45% from a year prior.
  • Gains from Investment Securities was $9.4 million for Q4 2024 at Kymera Therapeutics, up from -$2.1 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $48.8 million in Q1 2023 to a low of -$49.7 million in Q4 2023.
  • A 5-year average of $2.0 million and a median of $3.7 million in 2022 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: crashed 1417.97% in 2023, then soared 118.99% in 2024.
  • Kymera Therapeutics' Gains from Investment Securities stood at $5.8 million in 2020, then tumbled by 65.54% to $2.0 million in 2021, then skyrocketed by 84.34% to $3.7 million in 2022, then crashed by 1442.51% to -$49.7 million in 2023, then soared by 118.99% to $9.4 million in 2024.
  • Per Business Quant, the three most recent readings for KYMR's Gains from Investment Securities are $9.4 million (Q4 2024), -$2.1 million (Q3 2024), and -$49.7 million (Q4 2023).